|
|
 |
|
Viewing report
|
|
|
|
U.S. Market for Magnetic Resonance, Computed Tomography and Nuclear Medicine 2010 (Executive Summary)
iData Research, Dec 2010, Pages: 9
In 2009, the U.S. market for magnetic resonance (MRI), computed tomography (CT) and nuclear medicine was valued at over $5.1 billion. This market also includes contrast agents and injectors. The market declined in 2009 due to the deficit reduction act, which limited reimbursement for some imaging modalities, and the global economic recession of 2008 to 2009; however, the market is expected to recover by 2016.
This market includes:
Magnetic Resonance Imaging (MRI):
- Low-Field Magnetic Resonance Imaging
- Mid-Field Magnetic Resonance Imaging
- High-Field Magnetic Resonance Imaging
- Open Magnetic Resonance Imaging
- Intraoperative Magnetic Resonance Imaging
Computed Tomography (CT):
- 16/20 Slice Computed Tomography
- 32/40 Slice Computed Tomography
- 64 Slice Computed Tomography
- Ultra Premium Computed Tomography
Nuclear Medicine:
- Ultra Premium Computed Tomography
- PET/CT
- SPECT
- SPECT/CT
Contrast Agents and Injectors:
- X-Ray/CT Contrast Agents
- MRI Contrast Agents
- Ultrasound Contrast Agents
- Contrast Injectors
Within the magnetic resonance (MRI), computed tomography (CT) and nuclear medicine markets, companies such as Bracco, Covidien, GE Healthcare, Philips Healthcare and Siemens Healthcare lead the market. This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2016, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.
The executive summary of this report is also available for purchase.
Keywords:
Imaging, Magnetic Resonance, Computed Tomography and Nuclear Medicine, positron emission, contrast agent, injector
Also available
U.S. Market for Magnetic Resonance, Computed Tomography and Nuclear Medicine 2010
|
|
|
|
